JP2019513778A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513778A5 JP2019513778A5 JP2018553876A JP2018553876A JP2019513778A5 JP 2019513778 A5 JP2019513778 A5 JP 2019513778A5 JP 2018553876 A JP2018553876 A JP 2018553876A JP 2018553876 A JP2018553876 A JP 2018553876A JP 2019513778 A5 JP2019513778 A5 JP 2019513778A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- alkyl
- optionally substituted
- halo
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022036728A JP7420847B2 (ja) | 2016-04-15 | 2022-03-10 | Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 |
| JP2024002232A JP2024045202A (ja) | 2016-04-15 | 2024-01-11 | Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323602P | 2016-04-15 | 2016-04-15 | |
| US62/323,602 | 2016-04-15 | ||
| US201662348837P | 2016-06-10 | 2016-06-10 | |
| US62/348,837 | 2016-06-10 | ||
| US201662402997P | 2016-09-30 | 2016-09-30 | |
| US62/402,997 | 2016-09-30 | ||
| PCT/US2017/027918 WO2017181177A1 (en) | 2016-04-15 | 2017-04-17 | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036728A Division JP7420847B2 (ja) | 2016-04-15 | 2022-03-10 | Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513778A JP2019513778A (ja) | 2019-05-30 |
| JP2019513778A5 true JP2019513778A5 (enExample) | 2020-05-28 |
| JP7041070B2 JP7041070B2 (ja) | 2022-03-23 |
Family
ID=58664786
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553876A Expired - Fee Related JP7041070B2 (ja) | 2016-04-15 | 2017-04-17 | Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 |
| JP2022036728A Active JP7420847B2 (ja) | 2016-04-15 | 2022-03-10 | Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 |
| JP2024002232A Pending JP2024045202A (ja) | 2016-04-15 | 2024-01-11 | Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036728A Active JP7420847B2 (ja) | 2016-04-15 | 2022-03-10 | Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 |
| JP2024002232A Pending JP2024045202A (ja) | 2016-04-15 | 2024-01-11 | Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20170355712A1 (enExample) |
| EP (1) | EP3442947B1 (enExample) |
| JP (3) | JP7041070B2 (enExample) |
| KR (2) | KR20230130747A (enExample) |
| CN (1) | CN109153650A (enExample) |
| AU (3) | AU2017250369A1 (enExample) |
| BR (1) | BR112018071093A2 (enExample) |
| CA (1) | CA3021062A1 (enExample) |
| CL (2) | CL2018002928A1 (enExample) |
| CO (1) | CO2018012181A2 (enExample) |
| DK (1) | DK3442947T3 (enExample) |
| ES (1) | ES2953512T3 (enExample) |
| FI (1) | FI3442947T3 (enExample) |
| HU (1) | HUE064145T2 (enExample) |
| IL (3) | IL281319B2 (enExample) |
| LT (1) | LT3442947T (enExample) |
| MA (1) | MA44666A (enExample) |
| MX (2) | MX395342B (enExample) |
| PL (1) | PL3442947T3 (enExample) |
| PT (1) | PT3442947T (enExample) |
| SG (2) | SG10201913471VA (enExample) |
| SI (1) | SI3442947T1 (enExample) |
| TW (1) | TWI751155B (enExample) |
| WO (1) | WO2017181177A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017014163A (es) | 2015-05-06 | 2018-08-15 | Univ California | Moduladores de k-ras. |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| MX384836B (es) | 2016-03-07 | 2025-03-14 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis b |
| PT3442972T (pt) | 2016-04-15 | 2020-05-29 | Abbvie Inc | Inibidores de bromodomínio |
| US11278550B2 (en) | 2016-05-17 | 2022-03-22 | Duke University | Compositions and methods for the treatment of Prader-Willi syndrome |
| TWI808067B (zh) * | 2016-12-19 | 2023-07-11 | 美商雅酶股份有限公司 | 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法 |
| AU2018243749A1 (en) * | 2017-03-31 | 2019-11-21 | Epizyme, Inc. | Methods of using EHMT2 inhibitors |
| JP2020517600A (ja) * | 2017-04-20 | 2020-06-18 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｋ−Ｒａｓモジュレーター |
| US11672800B2 (en) | 2017-04-21 | 2023-06-13 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
| EP3675637A4 (en) | 2017-08-28 | 2021-05-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| EP3697419A4 (en) * | 2017-10-17 | 2021-08-18 | Epizyme, Inc. | AMINE SUBSTITUTION HETEROCYCLIC COMPOUNDS USED AS AND DERIVATIVES OF EHMT2 |
| WO2019079596A1 (en) * | 2017-10-18 | 2019-04-25 | Epizyme, Inc. | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES |
| WO2019079540A1 (en) * | 2017-10-18 | 2019-04-25 | Epizyme, Inc. | AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF |
| KR20200101332A (ko) * | 2017-10-18 | 2020-08-27 | 에피자임, 인코포레이티드 | 혈액 장애 예방 또는 치료에 있어서의 ehmt2 저해제의 사용 방법 |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| BR112020015431A2 (pt) | 2018-02-15 | 2020-12-08 | Nuvation Bio Inc. | Compostos heterocíclicos como inibidores de quinase |
| CN108822103A (zh) * | 2018-07-28 | 2018-11-16 | 刘凤娟 | 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用 |
| CN112955142A (zh) | 2018-09-21 | 2021-06-11 | 英安塔制药有限公司 | 官能化杂环化合物作为抗病毒剂 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
| IL283190B2 (en) | 2018-11-21 | 2025-08-01 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| TWI875756B (zh) * | 2019-05-05 | 2025-03-11 | 美商基尼特奇公司 | Ｃｄｋ抑制劑 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| GB201910608D0 (en) * | 2019-07-24 | 2019-09-04 | Enterprise Therapeutics Ltd | Compounds |
| AU2020328025A1 (en) | 2019-08-14 | 2022-03-03 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| JOP20220087A1 (ar) | 2019-10-11 | 2023-01-30 | Incyte Corp | أمينات ثنائية الحلقة كمثبطات لـ cdk2 |
| CA3163206A1 (en) | 2019-11-27 | 2021-06-03 | Riken | G9a inhibitor |
| PE20230240A1 (es) | 2019-12-20 | 2023-02-07 | Nuevolution As | Compuestos activos frente a receptores nucleares |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| MX2022013838A (es) | 2020-05-04 | 2023-02-22 | Amgen Inc | Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso. |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| CN111518015A (zh) * | 2020-05-20 | 2020-08-11 | 上海合全药物研发有限公司 | 一种叔丁基-8-氧亚基-2-氮杂螺[4.5]癸烷-2-甲酸基酯的制备方法 |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| MX2023009682A (es) | 2021-02-19 | 2023-10-30 | Sudo Biosciences Ltd | Inhibidores de tyk2 y sus usos. |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| CA3234693A1 (en) * | 2021-10-15 | 2023-04-20 | Tango Therapeutics, Inc. | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| KR20250040981A (ko) * | 2022-07-20 | 2025-03-25 | 주식회사 에스투시바이오 | 헤테로아릴 유도체 화합물 및 이의 용도 |
| CN115947692B (zh) * | 2022-12-28 | 2024-12-27 | 上海再启生物技术有限公司 | 一种制备2-氯-4-(甲氧基甲基)嘧啶的方法 |
| WO2024216164A1 (en) | 2023-04-13 | 2024-10-17 | Tango Therapeutics, Inc. | N2-((5-hydroxy)-2-pyridyl)-pyridine-2,4-diamine derivatives as ehmt1/2 modulators for the treatment of cancer |
| WO2025045203A1 (zh) * | 2023-09-01 | 2025-03-06 | 葆元生物医药科技(杭州)有限公司 | 杂环化合物及其中间体和应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP0585500A1 (en) * | 1992-09-04 | 1994-03-09 | Merrell Dow Pharmaceuticals Inc. | Diaryl piperazineacetamides as antimuscarinic agents |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| WO2003002544A1 (en) * | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
| EP1453516A2 (de) * | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| DK1534286T3 (da) * | 2002-07-29 | 2010-04-26 | Rigel Pharmaceuticals Inc | Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser |
| AU2004272288B2 (en) * | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| JP2008505907A (ja) * | 2004-07-06 | 2008-02-28 | アンジオン バイオメディカ コーポレイション | 癌治療を目的として肝細胞増殖因子およびｃ−ｍｅｔ活性を調整するキナゾリンモジュレーター |
| WO2007086911A2 (en) * | 2005-05-05 | 2007-08-02 | Sanofi-Aventis U.S. Llc | Stable nanoparticle formulations |
| EP1746096A1 (en) * | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
| JP2009501164A (ja) * | 2005-07-15 | 2009-01-15 | ４エスツェー アクチェンゲゼルシャフト | ２−アリールベンゾチアゾール及びその使用 |
| US9018209B2 (en) * | 2005-09-23 | 2015-04-28 | Yale University | Compounds and methods for the treatment of viruses and cancer |
| CA2628283C (en) * | 2005-11-01 | 2017-06-27 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| TW200736232A (en) * | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
| CA2647592C (en) * | 2006-05-26 | 2014-01-28 | Abbott Laboratories | Inhibitors of polo-like kinases |
| JP5328816B2 (ja) * | 2008-02-22 | 2013-10-30 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβの調節薬 |
| JP5802127B2 (ja) * | 2008-04-16 | 2015-10-28 | ポートラ ファーマシューティカルズ， インコーポレイテッド | Ｓｙｋ又はｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド類 |
| WO2010017122A2 (en) * | 2008-08-05 | 2010-02-11 | Targegen Inc. | Methods of treating thalassemia |
| EA201100438A1 (ru) * | 2008-09-03 | 2011-10-31 | Байер Кропсайенс Аг | 4-алкилзамещенные диаминопиримидины |
| WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
| PT2576541T (pt) * | 2010-06-04 | 2016-07-08 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| US20130244963A1 (en) * | 2010-09-30 | 2013-09-19 | Portola Pharmaceuticals, Inc. | Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide |
| KR101682417B1 (ko) * | 2011-02-25 | 2016-12-06 | 주식회사유한양행 | 다이아미노피리미딘 유도체 및 그의 제조방법 |
| WO2013054351A1 (en) * | 2011-08-08 | 2013-04-18 | Cadila Healthcare Limited | Heterocyclic compounds |
| WO2013033037A2 (en) * | 2011-08-26 | 2013-03-07 | The Regents Of The University Of California | Novel antiprion compounds |
| WO2013070852A2 (en) * | 2011-11-08 | 2013-05-16 | Emory University | Compounds and compositions used to epigenetically transform cells and methods related thereto |
| KR101452235B1 (ko) * | 2012-02-03 | 2014-10-22 | 서울대학교산학협력단 | 신규한 피리미딘계 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 ｒａｇｅ 수용체 관련 질환의 예방 또는 치료용 약학적 조성물 |
| WO2013140148A1 (en) * | 2012-03-19 | 2013-09-26 | Imperial Innovations Limited | Quinazoline compounds and their use in therapy |
| GB201209613D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| EP2903970A4 (en) * | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS |
| US9145412B2 (en) * | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| WO2015109109A1 (en) * | 2014-01-15 | 2015-07-23 | Forum Pharmaceuticals Inc. | Fused morpholinopyrimidines and methods of use thereof |
| EP3154957B1 (en) * | 2014-06-16 | 2019-11-20 | Fundacion para la Investigacion Medica Aplicada | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases |
-
2017
- 2017-04-17 WO PCT/US2017/027918 patent/WO2017181177A1/en not_active Ceased
- 2017-04-17 BR BR112018071093A patent/BR112018071093A2/pt active Search and Examination
- 2017-04-17 PL PL17720921.0T patent/PL3442947T3/pl unknown
- 2017-04-17 SG SG10201913471VA patent/SG10201913471VA/en unknown
- 2017-04-17 ES ES17720921T patent/ES2953512T3/es active Active
- 2017-04-17 DK DK17720921.0T patent/DK3442947T3/da active
- 2017-04-17 IL IL281319A patent/IL281319B2/en unknown
- 2017-04-17 SI SI201731402T patent/SI3442947T1/sl unknown
- 2017-04-17 AU AU2017250369A patent/AU2017250369A1/en not_active Abandoned
- 2017-04-17 CA CA3021062A patent/CA3021062A1/en active Pending
- 2017-04-17 FI FIEP17720921.0T patent/FI3442947T3/fi active
- 2017-04-17 HU HUE17720921A patent/HUE064145T2/hu unknown
- 2017-04-17 JP JP2018553876A patent/JP7041070B2/ja not_active Expired - Fee Related
- 2017-04-17 KR KR1020237028695A patent/KR20230130747A/ko not_active Ceased
- 2017-04-17 CN CN201780030129.9A patent/CN109153650A/zh active Pending
- 2017-04-17 TW TW106112816A patent/TWI751155B/zh not_active IP Right Cessation
- 2017-04-17 MX MX2018012622A patent/MX395342B/es unknown
- 2017-04-17 PT PT177209210T patent/PT3442947T/pt unknown
- 2017-04-17 MA MA044666A patent/MA44666A/fr unknown
- 2017-04-17 EP EP17720921.0A patent/EP3442947B1/en active Active
- 2017-04-17 SG SG11201808799SA patent/SG11201808799SA/en unknown
- 2017-04-17 KR KR1020187032892A patent/KR102571679B1/ko active Active
- 2017-04-17 IL IL307931A patent/IL307931A/en unknown
- 2017-04-17 LT LTEPPCT/US2017/027918T patent/LT3442947T/lt unknown
- 2017-05-22 US US15/601,888 patent/US20170355712A1/en not_active Abandoned
-
2018
- 2018-10-04 IL IL262140A patent/IL262140A/en unknown
- 2018-10-12 CL CL2018002928A patent/CL2018002928A1/es unknown
- 2018-10-15 MX MX2022010947A patent/MX2022010947A/es unknown
- 2018-11-13 CO CONC2018/0012181A patent/CO2018012181A2/es unknown
-
2019
- 2019-03-28 CL CL2019000815A patent/CL2019000815A1/es unknown
-
2020
- 2020-11-20 US US17/100,489 patent/US20210198277A1/en not_active Abandoned
-
2021
- 2021-10-07 AU AU2021245168A patent/AU2021245168B2/en not_active Ceased
-
2022
- 2022-03-10 JP JP2022036728A patent/JP7420847B2/ja active Active
-
2024
- 2024-01-11 JP JP2024002232A patent/JP2024045202A/ja active Pending
- 2024-01-25 AU AU2024200464A patent/AU2024200464A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513778A5 (enExample) | ||
| JP2012523457A5 (enExample) | ||
| JP2006524660A5 (enExample) | ||
| JP2016506961A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2013509431A5 (enExample) | ||
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| JP2010504346A5 (enExample) | ||
| JP2018524390A5 (enExample) | ||
| JP2009520685A5 (enExample) | ||
| JP2007524696A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| RU2015101102A (ru) | Гетероароматическое метильное производное циклического амина | |
| JP2013509392A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| JP2012528166A5 (enExample) | ||
| JP2014525420A5 (enExample) | ||
| ME00586B (me) | Fungicidni azociklični amidi | |
| JP2010535722A5 (enExample) | ||
| RU2012112471A (ru) | Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета | |
| JP2009532437A5 (enExample) | ||
| JP2019533650A5 (enExample) | ||
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2016540803A5 (enExample) | ||
| JP2018530582A5 (enExample) |